Can Allergy Shots Make Your Allergies Worse? Your Personal Risk Profile

Yes, temporarily — whether this happens to you specifically depends on your individual risk profile. Paradoxical worsening during SCIT build-up is more likely in patients with: more allergen sensitivities (polysensitization to 5+ allergens), high baseline symptom severity, peak-season start, rapid escalation protocols, and inadequate concurrent medication use. Patients who manage these risk factors through protocol customization — off-season start, slower escalation, daily antihistamines during build-up — may experience less pronounced worsening. The mechanism is well-established: before Treg-mediated tolerance develops, injections stimulate the Th2 immune pathway (Akdis & Akdis, JACI, 2015). Long-term, 60–90% achieve significant improvement.

Patients most likely to experience pronounced paradoxical worsening during SCIT build-up are those with multiple concurrent risk factors: polysensitization to 5 or more allergen categories (grass, trees, dust mites, cats, dogs, mold), high baseline symptom severity (TNSS above 8/12 before treatment), starting SCIT during their primary allergen season, undergoing rush or cluster immunotherapy protocols, and using no concurrent antihistamines or nasal corticosteroids during build-up. A patient who has all five risk factors — severely symptomatic, polysensitized, starting in peak season, with rush protocol and no pre-medication — faces much higher worsening risk than a patient with controlled symptoms starting in off-season with conventional escalation and daily antihistamines.

Yes — starting SCIT during an allergen-free or low-allergen season (typically winter for patients with spring pollen sensitivities) is one of the most effective strategies for reducing build-up phase worsening. When you start in winter, your build-up progresses for 3–6 months before environmental allergen exposure ramps up in spring. By the time allergen season arrives, you may already be approaching or at maintenance dose, which is much better tolerated. This timing strategy has been supported in clinical practice for decades — some allergists refer to starting SCIT pre-seasonally or off-seasonally as a standard protocol optimization for patients at high worsening risk. Discuss with your allergist whether the timing of your start date can be optimized.

Some clinical observations suggest that pediatric patients may tolerate SCIT build-up with less pronounced worsening than adults, possibly because children's immune systems are more plastic and more readily redirected toward tolerance. Children's immune systems have had less time to entrench Th2 patterns, and the regulatory mechanisms may be more responsive to immunotherapy-driven re-education. Adults, particularly those with long-standing established allergies, may experience more pronounced initial worsening because their Th2 patterns are more deeply established. This is one reason SCIT is frequently recommended in childhood — earlier treatment may offer smoother build-up and greater long-term disease modification. However, adult SCIT remains highly effective and should not be discouraged based on age considerations alone.

Several strategies can reduce worsening risk before and during SCIT. Before starting: complete comprehensive allergy testing to know your full sensitization profile, then time your start for the off-season if your sensitivity is primarily seasonal, optimize existing allergy medication control, and discuss conventional vs rush escalation protocols with your allergist based on your risk factors. During build-up: take daily non-sedating antihistamines (cetirizine 10mg or loratadine 10mg), use nasal corticosteroids consistently, avoid starting during a peak allergy period if possible, and communicate any symptom changes to your allergist promptly. If worsening becomes pronounced, ask your allergist about slowing the escalation pace — accepting a longer build-up period in exchange for better tolerability is a valid trade-off for high-risk patients.

Increased sneezing during SCIT build-up — particularly if it occurs within 30–60 minutes of injection — can be a sign of nasal mast cell activation from the allergen dose. This is part of the paradoxical worsening phenomenon: the same immune stimulation being delivered for therapeutic purposes also transiently amplifies allergic nasal symptoms. Sneezing that occurs during the 30-minute observation period should be reported to your care team as it may indicate a mild systemic reaction component requiring evaluation. Increased sneezing at home in the days following injections, if not severe, is a recognized build-up phase symptom that typically decreases as maintenance dose is reached. Daily antihistamines during build-up can measurably reduce injection-day and post-injection sneezing.